Ignite Creation Date:
2024-05-06 @ 6:24 PM
Last Modification Date:
2024-10-26 @ 2:47 PM
Study NCT ID:
NCT05646862
Status:
RECRUITING
Last Update Posted:
2024-06-21
First Post:
2022-12-02
Brief Title:
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive HER2-Negative PIK3CA Mutated Locally Advanced or Metastatic Breast Cancer Post CDK46i and Endocrine Combination Therapy
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-06-07
Start Date Type:
ACTUAL
Primary Completion Date:
2029-03-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-03-30
Completion Date Type:
ESTIMATED
First Submit Date:
2022-12-02
First Submit QC Date:
December 2 2022
Study First Post Date:
2022-12-12
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-09-24
Last Update Post Date:
2024-06-21
Last Update Post Date Type:
ACTUAL